Switching Semaglutide to Tirzepatide: Dose & Restart

If you are moving from semaglutide (Ozempic, Wegovy) to tirzepatide (Mounjaro, Zepbound), the question that matters most is deceptively simple: what dose do you start on? It is tempting to assume that if you finished semaglutide at a high maintenance dose, you can drop into tirzepatide somewhere near the top. That is not how it works. This piece explains what the labels actually support, why there is no shortcut, and how the timing of the switch is usually handled.

One thing up front: switching between prescription drugs is a clinical decision, full stop. Nothing here is a recommendation to switch or a dosing instruction — it is background to help you have a better conversation with your prescriber. Once you have a plan, you can map the new tirzepatide ramp on our GLP-1 titration schedule calculator.

There is no 1:1 dose conversion

The single most important thing to understand is that there is no official, FDA-approved conversion between semaglutide and tirzepatide doses. You cannot say “2.4 mg of semaglutide equals X mg of tirzepatide,” because the two drugs are not the same class of molecule doing the same thing.

Semaglutide is a GLP-1 receptor agonist — it acts on one receptor. Tirzepatide is a dual agonist that acts on both the GLP-1 and GIP receptors. Different mechanism, different potency curve, different tolerability profile. There is no pharmacological basis for a straight milligram-to-milligram swap, which is exactly why no conversion table exists on either label. We compare how the two drugs actually stack up on efficacy and side effects in our head-to-head explainer on semaglutide vs tirzepatide.

There is no FDA-approved dose conversion between semaglutide and tirzepatide — they are different drugs with different mechanisms.

The label starts everyone at 2.5 mg

Here is what the tirzepatide label does say, and it is unambiguous: initiate at 2.5 mg once weekly, then after four weeks increase to 5 mg, with further 2.5 mg increases allowed no sooner than every four weeks up to a maximum of 15 mg. The label explicitly notes that 2.5 mg “is a starting dose and is not an approved maintenance dose.”

Critically, the label makes no exception for people switching from another GLP-1. There is no “if the patient tolerated high-dose semaglutide, start at 5 mg” clause. From a strict on-label standpoint, everyone starting tirzepatide starts at 2.5 mg — regardless of what they were taking before. That 2.5 mg starting dose exists purely for tolerability, exactly as semaglutide’s 0.25 mg starting dose does.

Tirzepatide step	Weeks	Notes
2.5 mg	1–4	Starting dose only, not maintenance
5 mg	5–8	First maintenance-eligible dose
7.5 mg	9–12	If needed
10 mg	13–16	If needed
12.5 mg	17–20	If needed
15 mg	21+	Maximum

Some clinicians, weighing the fact that a patient already has months of GLP-1 exposure and tolerated a high semaglutide dose, may choose to move through the early tirzepatide steps faster than a true first-timer. But that is individualized clinical judgment, not a labeled conversion — and it is a decision only your prescriber can make. Do not assume it applies to you.

Why a high semaglutide dose doesn’t carry over

It feels counterintuitive to “step down” to 2.5 mg after finishing semaglutide near the top of its range. But the exposure doesn’t transfer, for two reasons.

First, the drugs aren’t interchangeable, so “high dose” of one says little about the equivalent of the other. Second, tolerance to GLP-1 side effects is somewhat drug- and dose-specific. Tirzepatide’s added GIP activity gives it a different side-effect footprint, and jumping straight to a high tirzepatide dose can bring on the nausea and GI upset that the starting dose is designed to avoid. Starting low and climbing is the same tolerability logic that governs any GLP-1 ramp — the reasoning is laid out in full in our piece on why slow titration wins.

Timing the switch

Because semaglutide clears slowly, the transition is usually timed rather than immediate. Semaglutide has a half-life of about one week, so roughly half of your last dose is still circulating seven days later, and it takes around five weeks to wash out fully.

In practice, that long tail is used as a bridge. The common approach is to take the first tirzepatide dose about one week after the last semaglutide injection — on the next scheduled weekly slot. That way there is no true gap in coverage: residual semaglutide is still providing appetite and glucose effects while low-dose tirzepatide builds up. The exact timing, again, is your prescriber’s call and may differ based on your situation.

What to expect after switching

A few honest framings, none of which are guarantees:

• Early side effects can return. Even coming off semaglutide, the first weeks on tirzepatide and each dose increase can bring GI symptoms as your gut adapts to the new drug.
• Progress may look flat at first. The 2.5 mg starting dose is a tolerability dose, not a treatment dose, so don’t read the first few weeks as a verdict on whether the switch is “working.”
• Prior intolerance is a flag. If semaglutide gave you significant nausea or vomiting, tell your prescriber — you may need a slower ramp or extra symptom management on tirzepatide too.

The bottom line

There is no conversion chart for switching semaglutide to tirzepatide because the drugs are pharmacologically different, and the tirzepatide label answers the dose question directly: start at 2.5 mg and climb its own ladder, with no built-in credit for the dose you were on before. The switch is typically timed about a week after your last semaglutide dose so the long semaglutide tail bridges the gap. Everything past that — how fast to climb, whether any acceleration is appropriate — is individualized and belongs to your prescriber.

This is educational information, not medical advice, and not a recommendation to switch. Have the conversation with your clinician first. When you have a plan, lay out your new tirzepatide schedule with our GLP-1 titration schedule calculator, and for the wider context on these drugs, see our complete GLP-1 guide.

Sources

• Zepbound (tirzepatide) HCP Dosage — Lilly
• Wegovy (semaglutide) Dosing and Administration — NovoMedLink (Novo Nordisk)
• Ozempic (semaglutide) Pen Dosing — Novo Nordisk
• Semaglutide (~1-week half-life) and tirzepatide pharmacokinetics: FDA prescribing information for Ozempic, Wegovy, and Zepbound.